



## Living Cell Technologies Limited

**ACN:** 104 028 042  
**ASX:** LCT  
**OTCQB:** LVCLY

### ASX ANNOUNCEMENT

## Results of LCT Rights Issue

---

**Sydney, Australia & Auckland, New Zealand, 24 December 2021** – Living Cell Technologies Limited (**LCT** or **Company**) advises that it has received valid applications for New Shares and New Options under its Rights Issue which was announced on 15 November 2021 and which closed on 21 December 2021, as follows:

	<b>Number of Shares</b>	<b>Number of Options</b>	<b>Amount</b>
Securities Taken Up	<b>45,158,037</b>	<b>15,052,679</b>	<b>361,264</b>
Shortfall Securities	<b>430,742,780</b>	<b>143,580,927</b>	<b>3,445,942</b>
Total	<b>475,900,817</b>	<b>158,633,606</b>	<b>3,807,207</b>

The Options are exercisable at \$0.015 and expire on 19 April 2024

The total amount raised was \$361,264 before the expenses of the Offer which were \$250,000.

It is expected that the New Shares and New Options will be issued on 30 December 2021.

The Directors of LCT have reserved the right to place the Shortfall Securities within three months after the close of the Offer at a price not less than the price under the Offer. 180 Markets Pty Limited has agreed to place the Shortfall Securities on a best endeavours basis. There is no guarantee that all or any of the Shortfall Securities will be placed.

Authorised for release by the Board of Living Cell Technologies Limited.

– Ends –

**For further information:** [www.lctglobal.com](http://www.lctglobal.com)

<b>At the Company:</b> Bernie Tuch Chief Executive Mobile: +61 411 461 604 <a href="mailto:bernietuch@lctglobal.com">bernietuch@lctglobal.com</a>	<b>At the Company:</b> Mark Licciardo Mertons Corporate Services Pty Ltd P: +61 03 8689 9997 <a href="mailto:markl@mertons.com.au">markl@mertons.com.au</a>
---	---

## **About Living Cell Technologies**

Living Cell Technologies Limited (ASX: LCT) is an Australasian biotechnology company that has focused on discovering and developing novel treatments for debilitating conditions such as diabetes and Parkinson's disease. LCT has secured initial funding for a third clinical with NTCELL (alginate coated capsule containing clusters of neonatal porcine choroid plexus cells) after completing Phase IIa and IIb clinical studies in Parkinson's disease. In a Phase IIb trial of NTCELL, there was not a statistically significant difference between the groups who received NTCELL and the placebo group at the 26-week study endpoint. However, at 24 months post-implant a clinically relevant effect was observed (<-6.45 points from baseline) in two of the three treatment groups. In the third clinical trial LCT will seek to alter the rate of disease progression in early-to-mid stage Parkinson's disease.

LCT has out-licensed DIABECCELL (alginate coated capsule containing neonatal porcine pancreatic cells) to Diatranz Otsuka Limited to continue the development of a cell therapy for type 1 diabetes in return for a royalty arrangement. LCT continues to seek new product project opportunities and also interactions that leverage its financial assets. LCT is listed on the Australian (ASX: LCT) and US (OTCQB: LVCLY) stock exchanges. The company is incorporated in Australia, with its operations based in Australia and New Zealand.

For more information visit [www.lctglobal.com](http://www.lctglobal.com) or follow @lctglobal on Twitter.

## **Forward-looking statements**

This document may contain certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "probable", "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates.

Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales.

In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects.

Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.